Company Overview of ALS Therapy Development Institute
215 1st Street
Cambridge, MA 02142-1236
Key Executives for ALS Therapy Development Institute
Chief Executive Officer and Chief Scientific Officer
Director of Communications & Public Affairs
Compensation as of Fiscal Year 2015.
ALS Therapy Development Institute Key Developments
ALS Therapy Development Institute Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:45 AM
Oct 7 15
ALS Therapy Development Institute Presents at 14th Annual BIO Investor Forum, Oct-21-2015 08:45 AM. Venue: Parc 55 Hotel, San Francisco, California, United States.
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
Dec 6 13
ALS Therapy Development Institute together with its wholly-owned subsidiary, Anelixis Therapeutics, announced that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1). Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a generalized role as a drug target for ALS treatments. The collaboration will explore the high-affinity human antibodies developed by Neurimmune that selectively target misfolded SOD1. In preclinical studies with transgenic mice, chronic antibody treatment significantly reduced SOD1 pathology and rescued spinal cord motor neurons, resulting in significantly reduced muscle atrophy, better motor functions and increased survival.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries